BioReference Laboratories, Inc. Sued by Myriad Genetics, Confident in Its Position

BioReference Laboratories, Inc. Sued by Myriad Genetics, Confident in Its

Company Not Yet Served, But Has Been Prepared for an Expected Action

ELMWOOD PARK, N.J., Oct. 22, 2013 (GLOBE NEWSWIRE) -- BioReference
Laboratories, Inc. (Nasdaq:BRLI) announces that Myriad Genetics has filed a
lawsuit against it in the Federal District Court in Utah alleging that
BioReference, through its genetic sequencing laboratory, GeneDx, Inc, is
infringing on its intellectual property by offering OncoGeneDx, its
comprehensive series of inherited cancers testing, including testing for
BRCA1/2. BioReference indicated that it is not surprised by the action and
that it is confident in its position.

BioReference has engaged the firm of Sterne, Kessler, Goldstein & Fox to
represent it in the action.The firm has represented the Company for many
years and has a superior reputation in the field of intellectual property,
especially in the area of genetic sequencing.BioReference stated that the
test was introduced in August of the current year, after careful consideration
in view of the Supreme Court's recent decisions in the field of genetic
diagnostics. Its team of geneticists and sequencing scientists have developed
several panels of tests for inherited cancers that will be valuable tools in
the management of cancer.As always for BioReference, the tests will be based
on innovative technology, will be affordable, and will be designed to provide
the service and support that has enabled BioReference to maintain its
sustained growth for the past two decades.

Myriad Genetics has taken similar steps to defend its exclusivity for BRCA1/2
testing by suing other laboratories that offer BRCA1/2 testing.The latest
action against BioReference is not unexpected and the Company is fully
prepared to defend against the action.BioReference is confident in its legal
position and its belief that patients are better served in this evolving area
of medicine by having choices and better access to alternative testing

About BioReference Laboratories, Inc.

BRLI is a clinical testing laboratory offering testing, information and
related services to physician offices, clinics, hospitals, employers and
governmental units.We believe that we are the fourth largest full-service
laboratory in the United States and the largest independent regional
laboratory in the Northeastern market.BRLI offers a comprehensive list of
laboratory testing services utilized by healthcare providers in the detection,
diagnosis, evaluation, monitoring and treatment of diseases.BRLI primarily
focuses on esoteric testing, molecular diagnostics, anatomical pathology,
women's health and correctional health care.

Statements included in this release that are not historical in nature, are
intended to be, and are hereby identified as "forward-looking statements".
Forward-looking statements may be identified by words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates," "will" or
words of similar meaning and include, but are not limited to, statements about
the expected future business and financial performance of Bio-Reference
Laboratories,Inc. and its subsidiaries. Statements looking forward in time
are included in this release pursuant to the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on forward-looking statements, which speak only as of the
date they are made and which reflect management's current estimates,
projections, expectations or beliefs and which involve risks and uncertainties
that could cause actual results and outcomes to be materially different.Risks
and uncertainties that may affect the future results of the company include,
but are not limited to, adverse results from pending or future government
investigations, our ability to sustain continued growth, lawsuits or private
actions, including any potential action involving Horizon as described herein,
the competitive environment, changes in government regulations, changing
relationships with customers, payers, suppliers and strategic partners,
including recent proposals by CMS described herein, and other and other risks
and uncertainties detailed from time to time in our filings with the
Securities and Exchange Commission.We undertake no obligation to publicly
update or review any forward-looking information, whether as a result of new
information, future developments or otherwise.


CONTACT: Tara Mackay
         Investor Relations Coordinator
         (201) 791-2600
         (201) 791-1941 (fax)
Press spacebar to pause and continue. Press esc to stop.